(PMC) A separate metabolism-focused paper reviewing human trial history makes a similar point: early signals of weight loss were not consistently reproduced in later studies, particularly when intensive diet/exercise protocols were included
Verdict# PT-141 is the definitive choice for sexual function applications
Injections are fast, targeted, and affordable
Description Overview 5-Amino-1MQ is a selective NNMT inhibitor that elevates cellular NAD+ and SAM to enhance mitochondrial function, fat oxidation, insulin sensitivity, and overall metabolic efficiency, with preclinical data indicating preferential visceral fat loss and a favorable safety profile
KLOW extends it for protocols that also want to study KPV
Ideal timing for testing: Before starting your GLP-1 medication (baseline) 4-6 weeks after starting treatment After any dose increase Quarterly during stable dosing Immediately if warning symptoms appear People at higher risk for electrolyte problems include those over 65, anyone with kidney disease, heart failure patients, people taking diuretics, and anyone with persistent GI symptoms lasting beyond the first 8-12 weeks of treatment
